# Title

 Food and Drugs. PART 640â€”ADDITIONAL STANDARDS FOR HUMAN BLOOD AND BLOOD PRODUCTS


# ID

 CFR-2018-title21-vol7.Pt. 640


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                                                                                 |
|:------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Money       | [(175.0, 'GBP')]                                                                                                                                                                                                                                                                                                                                       |
| Constraints | ['before', 'within', 'more than', 'not to exceed', 'greater than', 'maximum', 'less than', 'after', 'at least', 'exceed', 'no less than', 'prior to', 'greater', 'minimum of', 'minimum', 'no more than']                                                                                                                                              |
| Duration    | ['50.0 hour', '6.0 hour', '6.0 month', '7.0 day', '1 day', '30.0 day', '1.0 year', '24.0 hour', '12.0 month', '72.0 hour', '14.0 day', '8.0 week', '1.0 week', '1 week', '4.0 hour', '4.0 month', '60.0 day', '10.0 day', '8.0 hour', '11.0 hour', '16.0 week', '2.0 day']                                                                             |
| Condition   | ['until', 'unless', 'where', 'as soon as', 'provided that', 'when', 'if']                                                                                                                                                                                                                                                                              |
| Entities    | ['United States', 'Final', 'Heat', 'Such', 'Source', 'Immunization', 'Sodium', 'Platelet', 'Potency', 'Blood', 'Globulin', 'Turbid', 'Color', 'Whole', 'U.S. Standard', 'Eligibility', 'Plasma', 'Fresh', 'Food', 'Bulk', 'Laboratory', 'Agitation', 'Quality', 'Licensed', 'Albumin', 'That', 'Research', 'Plasmapheresis', 'Appropriate', 'Medical'] |
| Date        | ['2018-09-01']                                                                                                                                                                                                                                                                                                                                         |


# Structured Analysis With Context

 


## Money

| Money          | Context                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:---------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (175.0, 'GBP') | (4) The amount of whole blood, not including anticoagulant, removed from a donor during a manual plasmapheresis procedure or in any 2-day period shall not exceed 1,000 milliliters unless the donor's weight is 175 pounds or greater, in which case the amount of whole blood, not including anticoagulant, removed from the donor during a manual plasmapheresis procedure or in any 2-day period shall not exceed 1,200 milliliters. |
| (175.0, 'GBP') | (5) The amount of whole blood, not including anticoagulant, removed from a donor during a manual plasmapheresis procedure within a 7-day period shall not exceed 2,000 milliliters unless the donor's weight is 175 pounds or greater, in which case the amount of whole blood, not including anticoagulant, removed from a donor during a manual plasmapheresis procedure within a 7-day period shall not exceed 2,400 milliliters.     |
| (175.0, 'GBP') | (6) No more than 500 milliliters of whole blood shall be removed from a donor at one time, unless the donor's weight is 175 pounds or greater, in which case no more than 600 milliliters of whole blood shall be removed from the donor at one time.                                                                                                                                                                                    |


## Constraints

| Constraints   | Context                                                                                                                                        |
|:--------------|:-----------------------------------------------------------------------------------------------------------------------------------------------|
| prior to      | The blood container shall not be entered  prior to issue for any purpose except for blood collection                                           |
| within        | accompanied by instructions for sampling and for use within 6 hours after entering the container for sampling;                                 |
| after         | for sampling and for use within 6 hours after entering the container for sampling; (3) The blood                                               |
| maximum       | thoroughly and carefully by a method that gives maximum  assurance of a sterile container of blood.                                            |
| before        | for all samples shall bear the donor's identification before  collecting the samples.                                                          |
| before        | shall be attached to the whole blood container before blood collection, in a tamperproof manner that will                                      |
| after         | a temperature between 1 and 6 &#176;C immediately after collection unless the blood is to be further                                           |
| at least      | with different lots of antiserums are in agreement. at least                                                                                   |
| after         | Units testing positive  after additional more specific testing shall be labeled as                                                             |
| before        | a method that entails entering the final container before  the blood is used for transfusion.                                                  |
| prior to      | shall be inspected visually during storage and immediately prior to  issue.                                                                    |
| after         | product is defined as red blood cells remaining after  separating plasma from human blood.                                                     |
| after         | Immediately  after processing, the Red Blood Cells shall be placed                                                                             |
| after         | The product shall be inspected immediately  after separation of the plasma, periodically during storage, and                                   |
| before        | the donor of that unit of red cells. before                                                                                                    |
| within        | of the blood, or by normal undisturbed sedimentation. within                                                                                   |
| at least      | to assure that the donor's platelet count is at least  150,000 platelets per microliter (/&#181;L) before plateletpheresis begins.             |
| before        | is at least 150,000 platelets per microliter (/&#181;L) before  plateletpheresis begins.                                                       |
| prior to      | able to assess the donor's platelet count either prior to or immediately following the initiation of the collection                            |
| less than     | donation a donor whose pre-donation platelet count is less than 150,000 platelets/&#181;L until a subsequent pre-donation platelet count       |
| at least      | count indicates that the donor's platelet count is at least 150,000 platelets/&#181;L; and (3) You must take appropriate                       |
| no less than  | the donor's intended post-donation platelet count will be no less than  100,000 platelets/&#181;L.                                             |
|               |               (e) Frequency of plateletpheresis collection.                                                                                    |
| no more than  | (1) The donor may donate  no more than a total of 24 plateletpheresis collections during a                                                     |
| at least      | than 6 &#215; 1011 platelets, you must wait at least  2 calendar days before any subsequent plateletpheresis collection.                       |
| before        | you must wait at least 2 calendar days before  any subsequent plateletpheresis collection.                                                     |
| more than     | You must not attempt to collect  more than  2 collections within a 7 calendar day period.                                                      |
| within        | not attempt to collect more than 2 collections within  a 7 calendar day period.                                                                |
| at least      | &#215; 1011 or more platelets, you must wait at least  7 calendar days before any subsequent plateletpheresis collection.                      |
| before        | you must wait at least 7 calendar days before  any subsequent plateletpheresis collection.                                                     |
| not to exceed | For a period  not to exceed 30 calendar days, a donor may serve as                                                                             |
| at least      | responsible physician, and the donor's platelet count is at least 150,000 platelets/&#181;L, measured at the conclusion of the                 |
| before        | at the conclusion of the previous donation or before  initiating plateletpheresis for the current donation.                                    |
| at least      | unit of Red Blood Cells by apheresis unless at least 2 calendar days have passed and the extracorporeal                                        |
| less than     | the extracorporeal volume of the apheresis device is less than  100 milliliters.                                                               |
| before        | container shall be labeled with the donor's number before  the container is filled.                                                            |
| after         | (b) Immediately  after collection, the whole blood or plasma shall be                                                                          |
| within        | The platelet concentrate shall be separated  within  4 hours or                                                                                |
| within        | The platelet concentrate shall be separated  within  4 hours or                                                                                |
| less than     | visible hemolysis, that yields a count of not less than 5.5 &#215; 1010 platelets per unit in at                                               |
| at least      | than 5.5 &#215; 1010 platelets per unit in at least  75 percent of the units tested.                                                           |
| less than     | by the maintenance of a pH of not less than  6.2 during the storage period.                                                                    |
| maximum       | of platelets which has been stored for the maximum  dating period at the selected storage temperature.                                         |
| after         | Immediately  after resuspension, Platelets shall be placed in storage at                                                                       |
| less than     | (2) pH of not  less than 6.2 measured at the storage temperature of the                                                                        |
| within        | (1) The results of each test are received within 10 days of the preparation of the platelet                                                    |
| after         | a temperature between 1 and 6 &#176;C immediately after  the plasma is separated.                                                              |
| within        | shall be stored at &#8722;18 &#176;C or colder within 6 hours after transfer to the final container                                            |
| after         | at &#8722;18 &#176;C or colder within 6 hours after transfer to the final container or within the                                              |
| within        | shall be stored at &#8722;18 &#176;C or colder within 6 hours after transfer to the final container                                            |
| within        | an apheresis procedure, and placed in a freezer within  8 hours or                                                                             |
| within        | an apheresis procedure, and placed in a freezer within  8 hours or                                                                             |
| within        | at a temperature of 1 to 6 &#176;C within  4 hours after filling the final container or                                                        |
| after         | of 1 to 6 &#176;C within 4 hours after filling the final container or within the timeframe                                                     |
| within        | at a temperature of 1 to 6 &#176;C within  4 hours after filling the final container or                                                        |
| within        | separated from the red blood cells by centrifugation within  4 hours after completion of the phlebotomy or                                     |
| after         | red blood cells by centrifugation within 4 hours after completion of the phlebotomy or within the timeframe                                    |
| within        | separated from the red blood cells by centrifugation within  4 hours after completion of the phlebotomy or                                     |
| at least      | have been shown to produce a product with at least  250,000 platelets per microliter.                                                          |
| after         | a temperature between 20 and 24 &#176;C immediately after  filling the final container.                                                        |
| prior to      | as prescribed in subpart C of part 640, prior to  freezing the plasma.                                                                         |
| within        | be labeled as &#8220;Fresh Frozen Plasma,&#8221; if frozen within  6 hours after filling the final container or                                |
| after         | &#8220;Fresh Frozen Plasma,&#8221; if frozen within 6 hours after filling the final container or within the timeframe                          |
| within        | be labeled as &#8220;Fresh Frozen Plasma,&#8221; if frozen within  6 hours after filling the final container or                                |
| after         | be labeled &#8220;Plasma, Cryoprecipitate Reduced.&#8221; (3) Plasma remaining after both Platelets and Cryoprecipitated AHF have been removed |
| prior to      | so as to relate it to the donor. prior to                                                                                                      |
| after         | (1) The final product shall be inspected immediately  after separation of the plasma and shall not be                                          |
| before        | container shall be labeled with the donor's number before  the container is filled.                                                            |
| within        | The plasma shall be placed in a freezer within  8 hours after blood collection or                                                              |
| after         | be placed in a freezer within 8 hours after blood collection or within the timeframe specified in                                              |
| within        | The plasma shall be placed in a freezer within  8 hours after blood collection or                                                              |
| after         | (3) Immediately  after separation and freezing of the plasma, the plasma                                                                       |
| no less than  | has been shown to produce an average of no less than  80 units of antihemophilic factor per final container.                                   |
| prior to      | be added to the product by the manufacturer prior to  freezing.                                                                                |
| at least      | antihemophilic factor shall be conducted each month on at least  four representative containers of Cryoprecipitated AHF.                       |
| within        | received by the establishment licensed for Cryoprecipitated AHF within 30 days of the preparation of the cryoprecipitated                      |
| less than     | of antihemophilic factor in the containers tested is less than 80 units of antihemophilic factor per container, immediate                      |
| maximum       | thoroughly and carefully by a method that gives maximum  assurance of a sterile container of blood.                                            |
| at least      | the plasma separated from the formed elements, and at least  the red blood cells returned to the donor.                                        |
| at least      | physical examination or plasmapheresis, whichever comes first, and at least  every 4 months thereafter.                                        |
| before        | and so indicates by signing the donor's record before  such procedure is performed.                                                            |
| within        | composition of each component, and the collection records within 14 calendar days after the sample is drawn                                    |
| after         | and the collection records within 14 calendar days after the sample is drawn to determine whether or                                           |
| within        | If a determination is not made  within 14 calendar days, the donor must be deferred                                                            |
| within        | If the protein composition is not  within normal limits established by the testing laboratory, or                                              |
| less than     | laboratory, or if the total protein level is less than 6.0 grams per deciliter or more than 9.0                                                |
| more than     | is less than 6.0 grams per deciliter or more than 9.0 grams per deciliter in a plasma sample                                                   |
| greater       | or some other method that provides equal or greater  assurance of positively identifying the donor.                                            |
| exceed        | procedure or in any 2-day period shall not exceed 1,000 milliliters unless the donor's weight is 175                                           |
| greater       | unless the donor's weight is 175 pounds or greater , in which case the amount of whole                                                         |
| exceed        | procedure or in any 2-day period shall not exceed 1,000 milliliters unless the donor's weight is 175                                           |
| within        | from a donor during a manual plasmapheresis procedure within a 7-day period shall not exceed 2,000 milliliters                                 |
| exceed        | plasmapheresis procedure within a 7-day period shall not exceed 2,000 milliliters unless the donor's weight is 175                             |
| greater       | unless the donor's weight is 175 pounds or greater , in which case the amount of whole                                                         |
| within        | from a donor during a manual plasmapheresis procedure within a 7-day period shall not exceed 2,000 milliliters                                 |
| exceed        | plasmapheresis procedure within a 7-day period shall not exceed 2,000 milliliters unless the donor's weight is 175                             |
| no more than  | is 175 pounds or greater, in which case no more than 600 milliliters of whole blood shall be removed                                           |
| greater       | unless the donor's weight is 175 pounds or greater , in which case no more than 600                                                            |
| no more than  | is 175 pounds or greater, in which case no more than 600 milliliters of whole blood shall be removed                                           |
| after         | be separated from the red blood cells immediately after  blood collection.                                                                     |
| maximum       | The  maximum feasible volume of red blood cells shall be                                                                                       |
| before        | blood cells shall be returned to the donor before  another unit is collected.                                                                  |
| less than     | Evaluation and Research, and collection shall not occur less than 2 days apart or more frequently than twice                                   |
| prior to      | the original blood container, shall not be entered prior to issuance for any purpose except for filling with                                   |
| prior to      | which will relate it directly to the donor. prior to                                                                                           |
| maximum       | and, for plasma intended for injectable products, gives maximum  assurance of a sterile container of plasma.                                   |
| after         | plasma from two or more donors is pooled after the plasma has been removed from the red                                                        |
| after         | plasma from two or more donors is pooled after the plasma has been removed from the red                                                        |
| after         | Immediately  after filling, plasma intended for manufacturing into injectable products                                                         |
| prior to      | to the donor of that unit of plasma. prior to                                                                                                  |
| minimum of    | products must be held in quarantine for a minimum of 60 calendar days before it is released for                                                |
| before        | quarantine for a minimum of 60 calendar days before  it is released for further manufacturing.                                                 |
| after         | If,  after placing a donation in quarantine under this section,                                                                                |
| after         | a donor reaction is reported to the center after the donor has left the premises, the donor's                                                  |
| prior to      | (5) Source Plasma Liquid shall be inspected immediately  prior to  issuance.                                                                   |
| before        | &#8220;Source Plasma Salvaged.&#8221; The label shall be revised before issuance, and appropriate records shall be maintained identifying      |
| more than     | &#176;C and colder than &#8722;5 &#176;C for not more than 72 hours is exempt from the labeling requirements                                   |
| exceed        | that the episode of temperature elevation did not exceed 72 hours, that the temperature did not rise                                           |
| more than     | Bulk concentrate to be held  more than 1 week prior to further processing shall be                                                             |
| prior to      | concentrate to be held more than 1 week prior to further processing shall be stored in clearly identified                                      |
| more than     | of the sterile bulk solution, to be held more than 1 week prior to further processing shall be                                                 |
| prior to      | solution, to be held more than 1 week prior to further processing shall be stored in clearly identified                                        |
| prior to      | fraction to be held one week or less prior to further processing shall be stored in clearly identified                                         |
| within        | the final containers of Albumin (Human) shall begin within  24 hours after completion of filling.                                              |
| after         | of Albumin (Human) shall begin within 24 hours after  completion of filling.                                                                   |
| less than     | that the solution is heated continuously for not less than 10, or more than 11 hours, at an                                                    |
| more than     | heated continuously for not less than 10, or more than 11 hours, at an attained temperature of 60&#177;0.5                                     |
| at least      | be incubated at 20 to 35 &#176;C for at least 14 days following the heat treatment prescribed in                                               |
| at least      | Biologics Evaluation and Research, Food and Drug Administration. at least                                                                      |
| exceed        | potassium concentration of the final product shall not exceed  2 milliequivalents per liter.                                                   |
| after         | shall remain unchanged, as determined by visual inspection, after heating at 57 &#176;C for 50 hours, when                                     |
| exceed        | product, and at a temperature that shall not exceed the recommended storage temperature of the final product                                   |
| more than     | 5 percent, 20 percent, or 25 percent solution. more than                                                                                       |
| after         | 5 percent, 20 percent, or 25 percent solution. after                                                                                           |
| after         | more than 5 percent of the total protein. after                                                                                                |
| more than     | to that of alpha globulin that amounts to more than  5 percent of the total protein.                                                           |
| less than     | (2) Contains  less than 5 percent protein with a sedimentation coefficient greater                                                             |
| greater than  | than 5 percent protein with a sedimentation coefficient greater than  7.0 S.                                                                   |
| more than     | Bulk concentrate to be held  more than 1 week prior to further processing shall be                                                             |
| prior to      | concentrate to be held more than 1 week prior to further processing shall be stored in clearly identified                                      |
| more than     | of the sterile bulk solution) to be held more than 1 week prior to further processing, shall be                                                |
| prior to      | solution) to be held more than 1 week prior to further processing, shall be stored in clearly identified                                       |
| prior to      | fraction to be held one week or less prior to further processing shall be stored in clearly identified                                         |
| within        | containers of Plasma Protein Fraction (Human) shall begin within  24 hours after completion of filling.                                        |
| after         | Protein Fraction (Human) shall begin within 24 hours after  completion of filling.                                                             |
| less than     | that the solution is heated continuously for not less than 10 or more than 11 hours at an                                                      |
| more than     | heated continuously for not less than 10 or more than 11 hours at an attained temperature of 60&#177;0.5                                       |
| at least      | be incubated at 20 to 35 &#176;C for at least 14 days following the heat treatment prescribed in                                               |
| at least      | protein in the final product shall consist of at least 83 percent albumin, and no more than 17                                                 |
| no more than  | consist of at least 83 percent albumin, and no more than  17 percent globulins.                                                                |
| no more than  | of the total protein shall be gamma globulin. no more than                                                                                     |
| exceed        | potassium concentration of the final product shall not exceed  2 milliequivalents per liter.                                                   |
| after         | shall remain unchanged, as determined by visual inspection, after heating at 57 &#176;C for 50 hours, when                                     |
| exceed        | product, and at a temperature that shall not exceed the recommended storage temperature of the final product                                   |
| more than     | the Container Has Been Entered.&#8221; Immune Globulin (Human). more than                                                                      |
| after         | the Container Has Been Entered.&#8221; Immune Globulin (Human). after                                                                          |
| after         | shall not show any visible sign of gelation after  heating in a 12 &#215; 75 mm.                                                               |
| at least      | be capable of concentrating tenfold from source material at least two different antibodies; (2) not to affect the                              |
| prior to      | The globulin fraction may be stored in bulk  prior to further processing provided it is stored in clearly                                      |
| more than     | concentrate or a solid and containing alcohol or more than 5 percent moisture shall be stored at a                                             |
| less than     | as a solid free from alcohol and containing less than 5 percent moisture, shall be stored at a                                                 |
| less than     | of approximately equal amounts of material from not less than  1,000 donors.                                                                   |
| after         | The final product shall be sterilized promptly  after  solution.                                                                               |
| after         | be exposed to temperatures above 45 &#176;C, and after sterilization the product shall not be exposed to                                       |
| more than     | be exposed to temperatures above 32 &#176;C for more than  72 hours.                                                                           |
| at least      | Biologics Evaluation and Research, Food and Drug Administration. at least                                                                      |
| at least      | Each lot of final product shall contain  at least the minimum levels of antibodies for diphtheria, measles,                                    |
| minimum       | of final product shall contain at least the minimum levels of antibodies for diphtheria, measles, and for                                      |
| at least      | Each lot of final product shall contain  at least the minimum levels of antibodies for diphtheria, measles,                                    |
| after         | &#176;C the antibody level tests shall be performed after such storage with a sample of the stored                                             |
| minimum       | (b) Minimum levels. minimum                                                                                                                    |
| minimum       | The  minimum antibody levels are as follows: (1) No less                                                                                       |
| no less than  | than 2 units of diphtheria antitoxin per ml. no less than                                                                                      |
| within        | written requests under paragraph (a)(1) of this section within  5 working days.                                                                |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 6.0 hour   | Blood that has been removed from storage controlled by a licensed establishment shall not be reissued by a licensed establishment unless the following conditions are observed:                                                                                                                                                                                                                                                                                                                                                |
|            |               (1) The container has a tamper-proof seal when originally issued and this seal remains unbroken;                                                                                                                                                                                                                                                                                                                                                                                                                 |
|            |               (2) A segment is properly attached and has not been removed, except that blood lacking a properly attached segment may be reissued in an emergency provided it is accompanied by instructions for sampling and for use within 6 hours after entering the container for sampling;                                                                                                                                                                                                                                 |
|            |               (3) The blood has been stored continuously at 1 to 6 &#176;C and shipped between 1 and 10 &#176;C;                                                                                                                                                                                                                                                                                                                                                                                                               |
|            |               (4) The blood is held for observation until a significant inspection consistent with the requirements of &#167;&#8201;640.5(e) can be made.                                                                                                                                                                                                                                                                                                                                                                      |
| 12.0 month | (1) The donor may donate no more than a total of 24 plateletpheresis collections during a 12-month rolling period.                                                                                                                                                                                                                                                                                                                                                                                                             |
| 2.0 day    | (2) When you collect fewer than 6 &#215; 1011 platelets, you must wait at least 2 calendar days before any subsequent plateletpheresis collection.                                                                                                                                                                                                                                                                                                                                                                             |
| 7.0 day    | You must not attempt to collect more than 2 collections within a 7 calendar day period.                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| 7.0 day    | (3) When you collect 6 &#215; 1011 or more platelets, you must wait at least 7 calendar days before any subsequent plateletpheresis collection.                                                                                                                                                                                                                                                                                                                                                                                |
| 30.0 day   | For a period not to exceed 30 calendar days, a donor may serve as a dedicated plateletpheresis donor for a single recipient, in accordance with &#167;&#8201;610.40(c)(1) of this chapter, as often as is medically necessary, provided that the donor is in good health, as determined and documented by the responsible physician, and the donor's platelet count is at least 150,000 platelets/&#181;L, measured at the conclusion of the previous donation or before initiating plateletpheresis for the current donation. |
| 8.0 week   | (1) You must defer a donor from donating platelets by plateletpheresis or a co-collection of platelets and plasma by apheresis for 8 weeks if the donor has donated a unit of Whole Blood, or a single unit of Red Blood Cells by apheresis unless at least 2 calendar days have passed and the extracorporeal volume of the apheresis device is less than 100 milliliters.                                                                                                                                                    |
| 2.0 day    | (1) You must defer a donor from donating platelets by plateletpheresis or a co-collection of platelets and plasma by apheresis for 8 weeks if the donor has donated a unit of Whole Blood, or a single unit of Red Blood Cells by apheresis unless at least 2 calendar days have passed and the extracorporeal volume of the apheresis device is less than 100 milliliters.                                                                                                                                                    |
| 16.0 week  | (2) You must defer a donor from donating platelets for a period of 16 weeks if the donor donates two units of Red Blood Cells during a single apheresis procedure.                                                                                                                                                                                                                                                                                                                                                             |
| 8.0 week   | (3) You must defer a donor for 8 weeks or more if the cumulative red blood cell loss in any 8 week period could adversely affect donor health.                                                                                                                                                                                                                                                                                                                                                                                 |
| 8.0 week   | (3) You must defer a donor for 8 weeks or more if the cumulative red blood cell loss in any 8 week period could adversely affect donor health.                                                                                                                                                                                                                                                                                                                                                                                 |
| 1 day      | (g) The responsible physician must obtain the informed consent of a plateletpheresis donor on the first day of donation, and at subsequent intervals no longer than 1 year.                                                                                                                                                                                                                                                                                                                                                    |
| 1.0 year   | (g) The responsible physician must obtain the informed consent of a plateletpheresis donor on the first day of donation, and at subsequent intervals no longer than 1 year.                                                                                                                                                                                                                                                                                                                                                    |
| 4.0 hour   | The platelet concentrate shall be separated within 4 hours or within the timeframe specified in the directions for use for the blood collecting, processing, and storage system.                                                                                                                                                                                                                                                                                                                                               |
| 10.0 day   | Such testing shall not be considered as divided manufacturing, as described in &#167;&#8201;610.63 of this chapter, provided the following conditions are met:                                                                                                                                                                                                                                                                                                                                                                 |
|            |               (1) The results of each test are received within 10 days of the preparation of the platelet concentrate, and are maintained by the establishment licensed for Platelets so that they may be reviewed by an authorized representative of the Food and Drug Administration.                                                                                                                                                                                                                                        |
| 6.0 hour   | Plasma shall be separated from the red blood cells and shall be stored at &#8722;18 &#176;C or colder within 6 hours after transfer to the final container or within the timeframe specified in the directions for use for the blood collecting, processing, and storage system unless the product is to be stored as Liquid Plasma.                                                                                                                                                                                           |
| 8.0 hour   | The plasma must be separated from the red blood cells or collected by an apheresis procedure, and placed in a freezer within 8 hours or within the timeframe specified in the directions for use for the blood collecting, processing, and storage system, and stored at &#8722;18 &#176;C or colder.                                                                                                                                                                                                                          |
| 4.0 hour   | Liquid Plasma shall be separated from the red blood cells and shall be stored at a temperature of 1 to 6 &#176;C within 4 hours after filling the final container or within the timeframe specified in the directions for use for the blood collecting, processing, and storage system.                                                                                                                                                                                                                                        |
| 4.0 hour   | The plasma shall be separated from the red blood cells by centrifugation within 4 hours after completion of the phlebotomy or within the timeframe specified in the directions for use for the blood collecting, processing, and storage system.                                                                                                                                                                                                                                                                               |
| 6.0 hour   | The remaining plasma may be labeled as &#8220;Fresh Frozen Plasma,&#8221; if frozen within 6 hours after filling the final container or within the timeframe specified in the directions for use for the blood collecting, processing, and storage system.                                                                                                                                                                                                                                                                     |
| 8.0 hour   | (2) The plasma shall be placed in a freezer within 8 hours after blood collection or within the timeframe specified in the directions for use for the blood collecting, processing, and storage system.                                                                                                                                                                                                                                                                                                                        |
| 30.0 day   | (b) The results of each test are received by the establishment licensed for Cryoprecipitated AHF within 30 days of the preparation of the cryoprecipitated antihemophilic factor and are maintained at that establishment so that they may be reviewed by an authorized representative of the Food and Drug Administration.                                                                                                                                                                                                    |
| 4.0 month  | The plasmapheresis procedure shall meet the following requirements:                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|            |               (1)(i) Except as provided under &#167;&#8201;630.25 of this chapter, the responsible physician must draw a sample of blood from each donor on the day of the initial physical examination or plasmapheresis, whichever comes first, and at least every 4 months thereafter.                                                                                                                                                                                                                                      |
| 4.0 month  | (ii) A repeat donor who does not return for plasmapheresis at the time the 4-month sample is due to be collected may be plasmapheresed on the day he appears: Provided, That no longer than 6 months has elapsed since the last sample was collected, and the responsible physician approves the plasmapheresis procedure and so indicates by signing the donor's record before such procedure is performed.                                                                                                                   |
| 6.0 month  | (ii) A repeat donor who does not return for plasmapheresis at the time the 4-month sample is due to be collected may be plasmapheresed on the day he appears: Provided, That no longer than 6 months has elapsed since the last sample was collected, and the responsible physician approves the plasmapheresis procedure and so indicates by signing the donor's record before such procedure is performed.                                                                                                                   |
| 4.0 month  | The sample for the 4-month tests shall be collected on the day of the donor's return.                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 6.0 month  | (iii) A repeat donor from whom the plasmapheresis center is unable to obtain a sample for testing as prescribed in paragraph (b)(1)(i) of this section for a total period exceeding 6 months shall be processed as a new donor.                                                                                                                                                                                                                                                                                                |
| 14.0 day   | (2)(i) Except as provided under &#167;&#8201;630.25 of this chapter, the responsible physician must review the accumulated laboratory data, including any tracings of the plasma or serum protein electrophoresis pattern, the calculated values of the protein composition of each component, and the collection records within 14 calendar days after the sample is drawn to determine whether or not the donor should be deferred from further donation.                                                                    |
| 14.0 day   | If a determination is not made within 14 calendar days, the donor must be deferred pending such a determination.                                                                                                                                                                                                                                                                                                                                                                                                               |
| 2.0 day    | (4) The amount of whole blood, not including anticoagulant, removed from a donor during a manual plasmapheresis procedure or in any 2-day period shall not exceed 1,000 milliliters unless the donor's weight is 175 pounds or greater, in which case the amount of whole blood, not including anticoagulant, removed from the donor during a manual plasmapheresis procedure or in any 2-day period shall not exceed 1,200 milliliters.                                                                                       |
| 2.0 day    | (4) The amount of whole blood, not including anticoagulant, removed from a donor during a manual plasmapheresis procedure or in any 2-day period shall not exceed 1,000 milliliters unless the donor's weight is 175 pounds or greater, in which case the amount of whole blood, not including anticoagulant, removed from the donor during a manual plasmapheresis procedure or in any 2-day period shall not exceed 1,200 milliliters.                                                                                       |
| 7.0 day    | (5) The amount of whole blood, not including anticoagulant, removed from a donor during a manual plasmapheresis procedure within a 7-day period shall not exceed 2,000 milliliters unless the donor's weight is 175 pounds or greater, in which case the amount of whole blood, not including anticoagulant, removed from a donor during a manual plasmapheresis procedure within a 7-day period shall not exceed 2,400 milliliters.                                                                                           |
| 7.0 day    | (5) The amount of whole blood, not including anticoagulant, removed from a donor during a manual plasmapheresis procedure within a 7-day period shall not exceed 2,000 milliliters unless the donor's weight is 175 pounds or greater, in which case the amount of whole blood, not including anticoagulant, removed from a donor during a manual plasmapheresis procedure within a 7-day period shall not exceed 2,400 milliliters.                                                                                           |
| 2.0 day    | (8) The volume of plasma collected during an automated plasmapheresis collection procedure shall be consistent with the volumes specifically approved by the Director, Center for Biologics Evaluation and Research, and collection shall not occur less than 2 days apart or more frequently than twice in a 7-day period.                                                                                                                                                                                                    |
| 7.0 day    | (8) The volume of plasma collected during an automated plasmapheresis collection procedure shall be consistent with the volumes specifically approved by the Director, Center for Biologics Evaluation and Research, and collection shall not occur less than 2 days apart or more frequently than twice in a 7-day period.                                                                                                                                                                                                    |
| 6.0 month  | Establishments must ensure that Source Plasma donated by paid donors not be used for further manufacturing into injectable products until the donor has a record of being found eligible to donate in accordance with &#167;&#8201;630.10 of this chapter and a record of negative test results on all tests required under &#167;&#8201;610.40(a) of this chapter on two occasions in the past 6 months.                                                                                                                      |
| 60.0 day   | Source Plasma donated by paid donors determined to be suitable for further manufacturing into injectable products must be held in quarantine for a minimum of 60 calendar days before it is released for further manufacturing.                                                                                                                                                                                                                                                                                                |
| 72.0 hour  | (2) Source Plasma intended for manufacture into injectable products that is exposed inadvertently (i.e., an unforeseen occurrence in spite of compliance with good manufacturing practice) to one episode of storage temperature fluctuation that is warmer than &#8722;20 &#176;C and colder than &#8722;5 &#176;C for not more than 72 hours is exempt from the labeling requirements of paragraph (a)(1) of this section, provided that the plasma has been and remains frozen solid.                                       |
| 72.0 hour  | Appropriate records shall be maintained identifying the units involved, describing their disposition, explaining fully the conditions that caused the inadvertent temperature exposure, and documenting that the episode of temperature elevation did not exceed 72 hours, that the temperature did not rise to warmer than &#8722;5 &#176;C in storage, and that the plasma remained frozen solid throughout the period of elevated temperature.                                                                              |
| 1.0 week   | Bulk concentrate to be held more than 1 week prior to further processing shall be stored in clearly identified closed vessels at a temperature of &#8722;5 &#176;C or colder.                                                                                                                                                                                                                                                                                                                                                  |
| 1.0 week   | Any other bulk form of the product, exclusive of the sterile bulk solution, to be held more than 1 week prior to further processing shall be stored in clearly identified closed vessels at a temperature of 5 &#176;C or colder.                                                                                                                                                                                                                                                                                              |
| 1 week     | Any bulk fraction to be held one week or less prior to further processing shall be stored in clearly identified closed vessels at a temperature of 5 &#176;C or colder.                                                                                                                                                                                                                                                                                                                                                        |
| 24.0 hour  | Heating of the final containers of Albumin (Human) shall begin within 24 hours after completion of filling.                                                                                                                                                                                                                                                                                                                                                                                                                    |
| 11.0 hour  | Heat treatment shall be conducted so that the solution is heated continuously for not less than 10, or more than 11 hours, at an attained temperature of 60&#177;0.5 &#176;C.                                                                                                                                                                                                                                                                                                                                                  |
| 14.0 day   | All final containers of Albumin (Human) shall be incubated at 20 to 35 &#176;C for at least 14 days following the heat treatment prescribed in paragraph (e) of this section.                                                                                                                                                                                                                                                                                                                                                  |
| 50.0 hour  | A final container sample of Albumin (Human) shall remain unchanged, as determined by visual inspection, after heating at 57 &#176;C for 50 hours, when compared to its control consisting of a sample, from the same lot, which has not undergone this heating.                                                                                                                                                                                                                                                                |
| 4.0 hour   | Do Not Begin Administration More Than 4 Hours After the Container Has Been Entered.&#8221;;                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|            |               (c) The need for additional fluids when 20 percent or 25 percent albumin is administered to a patient with marked dehydration;                                                                                                                                                                                                                                                                                                                                                                                   |
|            |               (d) The protein concentration, expressed as a 4 percent, 5 percent, 20 percent, or 25 percent solution.                                                                                                                                                                                                                                                                                                                                                                                                          |
| 1.0 week   | Bulk concentrate to be held more than 1 week prior to further processing shall be stored in clearly identified closed vessels at a temperature of &#8722;5 &#176;C or colder.                                                                                                                                                                                                                                                                                                                                                  |
| 1.0 week   | Any other bulk form of the product (exclusive of the sterile bulk solution) to be held more than 1 week prior to further processing, shall be stored in clearly identified closed vessels at a temperature of 5 &#176;C or colder.                                                                                                                                                                                                                                                                                             |
| 1 week     | Any bulk fraction to be held one week or less prior to further processing shall be stored in clearly identified closed vessels at a temperature of 5 &#176;C or colder.                                                                                                                                                                                                                                                                                                                                                        |
| 24.0 hour  | Heating of the final containers of Plasma Protein Fraction (Human) shall begin within 24 hours after completion of filling.                                                                                                                                                                                                                                                                                                                                                                                                    |
| 11.0 hour  | Heat treatment shall be conducted so that the solution is heated continuously for not less than 10 or more than 11 hours at an attained temperature of 60&#177;0.5 &#176;C.                                                                                                                                                                                                                                                                                                                                                    |
| 14.0 day   | All final containers of Plasma Protein Fraction (Human) shall be incubated at 20 to 35 &#176;C for at least 14 days following the heat treatment prescribed in paragraph (e) of this section.                                                                                                                                                                                                                                                                                                                                  |
| 50.0 hour  | A final container sample of Plasma Protein Fraction (Human) shall remain unchanged, as determined by visual inspection, after heating at 57 &#176;C for 50 hours, when compared to its control consisting of a sample, from the same lot, which has not undergone this heating.                                                                                                                                                                                                                                                |
| 4.0 hour   | Do Not Begin Administration More than 4 Hours After the Container Has Been Entered.&#8221;                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|            |               Immune Globulin (Human).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 4.0 hour   | stoppered glass tube at 57 &#176;C for 4 hours.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 72.0 hour  | At no time during processing shall the product be exposed to temperatures above 45 &#176;C, and after sterilization the product shall not be exposed to temperatures above 32 &#176;C for more than 72 hours.                                                                                                                                                                                                                                                                                                                  |


## Condition

| Condition     | Context                                                                                                                                         |
|:--------------|:------------------------------------------------------------------------------------------------------------------------------------------------|
| when          | for any purpose except for blood collection or when the method of processing requires use of a                                                  |
| unless        | shall not be reissued by a licensed establishment unless the following conditions are observed: (1) The container                               |
| when          | observed: (1) The container has a tamper-proof seal when originally issued and this seal remains unbroken; (2)                                  |
| until         | &#176;C; (4) The blood is held for observation until a significant inspection consistent with the requirements of                               |
| where         | the blood establishment and at any other place where  the bleeding is performed.                                                                |
| when          | be collected shall be in the blood container when  it is sterilized.                                                                            |
| if            | which may be closed or may be vented if  the vent protects the blood against contamination.                                                     |
| when          | shall be provided with each unit of blood when issued or reissued except as provided in &#167;&#8201;640.2(c)(2)                                |
| unless        | between 1 and 6 &#176;C immediately after collection unless the blood is to be further processed into                                           |
| until         | a temperature range between 1 and 10 &#176;C until  arrival at the processing laboratory.                                                       |
| until         | made and the unit shall not be issued until grouping tests by different methods or with different                                               |
| if            | (formerly Du).&#8221; Blood may be labeled &#8220;Rh Negative&#8221; if  further testing is negative.                                           |
| if            | (formerly Du).&#8221; Blood may be labeled &#8220;Rh Negative&#8221; if  further testing is negative.                                           |
| when          | 6 &#176;C at all times, including that time when the plasma is being frozen for removal of                                                      |
| if            | The product shall not be issued  if there is any abnormality in color or physical                                                               |
| if            | The product shall not be issued  if there is any abnormality in color or physical                                                               |
| when          | unit of Whole Blood or Red Blood Cells when  issued or reissued.                                                                                |
| when          | shall be left with the red cells except when a cryoprotective substance or additive solution is added                                           |
| unless        | Blood Cells shall be the original blood containers unless  the method of processing requires a different container.                             |
| if            | At the time of filing,  if  a d                                                                                                                 |
| if            | serve as the source of platelets for transfusion if the donor has recently ingested a drug that                                                 |
| if            | serve as the source of platelets for transfusion if the donor has recently ingested a drug that                                                 |
| unless        | ingested a drug that adversely affects platelet function unless the unit is labeled to identify the ingested                                    |
| if            | must assess and monitor the donor's platelet count. if                                                                                          |
| if            | &#215; 1011 or more platelets from that donor. if                                                                                               |
| until         | pre-donation platelet count is less than 150,000 platelets/&#181;L until a subsequent pre-donation platelet count indicates that the            |
| when          | 2 calendar days before any subsequent plateletpheresis collection. when                                                                         |
| when          | 7 calendar days before any subsequent plateletpheresis collection. when                                                                         |
| provided that | this chapter, as often as is medically necessary, provided that the donor is in good health, as determined                                      |
| if            | platelets and plasma by apheresis for 8 weeks if the donor has donated a unit of Whole                                                          |
| unless        | single unit of Red Blood Cells by apheresis unless at least 2 calendar days have passed and                                                     |
| if            | donating platelets for a period of 16 weeks if the donor donates two units of Red Blood                                                         |
| if            | defer a donor for 8 weeks or more if the cumulative red blood cell loss in any                                                                  |
| if            | (BLA) or an approved supplement to a BLA. if                                                                                                    |
| unless        | Platelets must not be pooled during processing  unless the platelets are pooled as specified in the                                             |
| unless        | held in storage between 20 and 24 &#176;C unless it must be transported from the collection center                                              |
| until         | to a range between 20 and 24 &#176;C until it arrives at the processing laboratory where it                                                     |
| where         | &#176;C until it arrives at the processing laboratory where it shall be held between 20 and 24                                                  |
| until         | to a range between 20 and 24 &#176;C until it arrives at the processing laboratory where it                                                     |
| if            | Agitation is optional  if stored at a temperature between 1 and 6                                                                               |
| if            | taken and a record maintained of such action. if                                                                                                |
| until         | for Plasma, Fresh Frozen Plasma, and Liquid Plasma, until the plasma is removed, the whole blood must                                           |
| until         | Plasma must be maintained as prescribed in &#167;&#8201;640.24 until  the plasma is removed.                                                    |
| unless        | for the blood collecting, processing, and storage system unless the product is to be stored as Liquid                                           |
| if            | product shall be maintained throughout the storage period, if stored at a temperature of 20 to 24                                               |
| if            | plasma may be labeled as &#8220;Fresh Frozen Plasma,&#8221; if frozen within 6 hours after filling the final                                    |
| if            | plasma and shall not be issued for transfusion if there is (i) any abnormality in color or                                                      |
| if            | in a manner that shows evidence of thawing if records of continuous monitoring of the storage temperature                                       |
| if            | evidence of thawing and shall not be issued if  there is any evidence of thawing.                                                               |
| until         | derived shall be maintained as required under &#167;&#8201;640.24 until  the platelets are removed.                                             |
| if            | of that section shall not apply), and 640.65. if                                                                                                |
| until         | stored and maintained at &#8722;18 &#176;C or colder until thawing of the plasma for further processing to                                      |
| if            | taken and a record maintained of such action. if                                                                                                |
| if            | which may be closed, or may be vented if the vent protects the blood cells and plasma                                                           |
| if            | normal limits established by the testing laboratory, or if the total protein level is less than 6.0                                             |
| until         | sample, the donor must be deferred from donation until  the protein composition returns to acceptable levels.                                   |
| when          | Reinstatement of the donor into the plasmapheresis program  when the donor's protein composition values have returned to                        |
| until         | test for syphilis shall not be plasmapheresed again until the donor's serum is tested and found to                                              |
| unless        | any 2-day period shall not exceed 1,000 milliliters unless the donor's weight is 175 pounds or greater,                                         |
| unless        | a 7-day period shall not exceed 2,000 milliliters unless the donor's weight is 175 pounds or greater,                                           |
| unless        | be removed from a donor at one time, unless the donor's weight is 175 pounds or greater,                                                        |
| where         | shall be on file at each plasmapheresis center where  immunizations are performed.                                                              |
| if            | Plasma from the same donor may be pooled if such units are collected during one plasmapheresis procedure:                                       |
| if            | of individual plasma containers need not be made if the records of continuous monitoring of the storage                                         |
| until         | be used for further manufacturing into injectable products until the donor has a record of being found                                          |
| if            | not be recorded on the individual donor record if such information is maintained on the premises of                                             |
| where         | maintained on the premises of the plasmapheresis center where  the donor's plasma has been collected.                                           |
| where         | in accordance with &#167;&#8201;630.15(b)(1) of this chapter and, where applicable, &#167;&#8201;630.15(b)(5) of this chapter must document the |
| when          | of the donor as a plasmapheresis donor and, when  applicable, as an immunized donor.                                                            |
| if            | indicate by number those units that are reactive. if                                                                                            |
| if            | shall contain a full explanation for the rejection. if                                                                                          |
| if            | the donor and the outcome of the incident. if                                                                                                   |
| as soon as    | Evaluation and Research shall be notified by telephone as soon as  possible.                                                                    |
| if            | than + 10 &#176;C may be issued only if labeled as &#8220;Source Plasma Salvaged.&#8221; The label shall                                        |
| provided that | labeling requirements of paragraph (a)(1) of this section, provided that  the plasma has been and remains frozen solid.                         |
| unless        | Source material shall not contain an additive  unless it is shown that the processing method yields                                             |
| when          | The pH shall be 6.9 &#177;0.5  when measured in a solution of the final product                                                                 |
| when          | after heating at 57 &#176;C for 50 hours, when compared to its control consisting of a sample,                                                  |
| if            | prominent position on the label, &#8220;Do Not Use if  Turbid.                                                                                  |
| when          | Been Entered.&#8221;; (c) The need for additional fluids when 20 percent or 25 percent albumin is administered                                  |
| unless        | Source material shall not contain an additive  unless it is shown that the processing method yields                                             |
| when          | The pH shall be 7.0 &#177;0.3  when measured in a solution of the final product                                                                 |
| when          | after heating at 57 &#176;C for 50 hours, when compared to its control consisting of a sample,                                                  |
| if            | prominent position on the label, &#8220;Do Not Use if  Turbid.                                                                                  |
| unless        | than citrate or acid citrate dextrose anticoagulant solution, unless it is shown that the processing method yields                              |
| when          | of final container material shall be 6.8 &#177;0.4 when measured in a solution diluted to 1 percent                                             |
| when          | (2) A measles neutralizing antibody level that,  when compared with that of a reference material designated                                     |
| when          | The Director, CBER, shall notify manufacturers  when a new reference material will be used and                                                  |
| when          | 2, or Type 3 neutralizing antibody level that, when compared with that of a reference material designated                                       |
| when          | The Director, CBER, shall notify manufacturers  when a new reference material will be used and                                                  |
| if            | chapter; (2) An oral request from an establishment, if  there are d                                                                             |
| if            | Regulations regarding blood, blood components, or blood products, if a variance under this section is necessary to                              |
| if            | a written notice of the exception or alternative. if                                                                                            |


## Entities

| Entities       | Context                                                                                                                               |
|:---------------|:--------------------------------------------------------------------------------------------------------------------------------------|
| Food           | Food  and Drugs.                                                                                                                      |
| Research       | that the Director, Center for Biologics Evaluation and Research , may approve arrangements, upon joint request of                     |
| Blood          | Blood that has been removed from storage controlled by                                                                                |
| Blood          | Blood containers and donor sets shall be pyrogen-free, sterile                                                                        |
| Blood          | Blood from which a component is to be prepared                                                                                        |
| Research       | by the Director, Center for Biologics Evaluation and Research , of a supplement to the biologics license                              |
| Eligibility    | Eligibility  of donor.                                                                                                                |
| Source         | (b)  Source blood may also be derived from Whole Blood                                                                                |
| Whole          | (b) Source blood may also be derived from  Whole Blood manufactured in accordance with applicable provisions of                       |
| Blood          | Blood  from which Red                                                                                                                 |
| Final          | Final containers used for Red Blood Cells shall be                                                                                    |
| Research       | by the Director, Center for Biologics Evaluation and Research , as adequately demonstrating through in vivo cell                      |
| Eligibility    | Eligibility  of donors.                                                                                                               |
| Agitation      | Agitation is optional if stored at a temperature between                                                                              |
| Research       | by the Director, Center for Biologics Evaluation and Research , Food and Drug Administration.                                         |
| Research       | undertaken by the Center for Biologics Evaluation and Research , Food and Drug Administration.                                        |
| Plasma         | Plasma .                                                                                                                              |
| Eligibility    | Eligibility  of donors.                                                                                                               |
| Plasma         | When whole blood is intended for  Plasma , Fresh Frozen                                                                               |
| Whole          | Whole blood intended for Platelet Rich Plasma must be                                                                                 |
| Plasma         | (b) Manufacturers of  Plasma collected by plasmapheresis shall have testing and recordkeeping                                         |
| Plasma         | Plasma shall be separated from the red blood cells                                                                                    |
| Fresh          | Fresh frozen plasma shall be prepared from blood collected                                                                            |
| Platelet       | Platelet rich plasma shall be prepared from blood collected                                                                           |
| Plasma         | (e) Modifications of  Plasma .                                                                                                        |
| Plasma         | possible to separate Platelets and/or Cryoprecipitated AHF from Plasma .                                                              |
| Plasma         | shall be collected as described in &#167;&#8201;640.32 for Plasma .                                                                   |
| Plasma         | The remaining plasma shall be labeled &#8220; Plasma , Cryoprecipitate Reduced.&#8221;                                                |
|                |               (3)                                                                                                                     |
| Plasma         | The remaining plasma shall be labeled &#8220; Plasma , Cryoprecipitate Reduced.&#8221;                                                |
|                |               (3)                                                                                                                     |
| Eligibility    | Eligibility  of donors.                                                                                                               |
| Whole          | Whole blood from which both Platelets and Cryoprecipitated AHF                                                                        |
| U.S. Standard  | U.S. Standard  preparation.                                                                                                           |
| U.S. Standard  | A  U.S. Standard Antihemophilic Factor (Factor VIII) preparation may be obtained                                                      |
| Research       | obtained from the Center for Biologics Evaluation and Research , (HFM-407) (see mailing addresses in &#167;&#8201;600.2 of            |
| Quality        | Quality  control test for potency.                                                                                                    |
| Research       | by the Director, Center for Biologics Evaluation and Research , Food and Drug Administration.                                         |
| Research       | undertaken by the Center for Biologics Evaluation and Research , Food and Drug Administration.                                        |
| Source         | Source  Plasma.                                                                                                                       |
| Blood          | Blood containers and donor sets must be pyrogen-free, sterile,                                                                        |
| Plasmapheresis | Plasmapheresis .                                                                                                                      |
| Such           | Such system shall include either a photograph of each                                                                                 |
| Research       | by the Director, Center for Biologics Evaluation and Research , and collection shall not occur less than                              |
| Research       | by the Director, Center for Biologics Evaluation and Research , Food and Drug Administration.                                         |
| Immunization   | Immunization procedures shall be on file at each plasmapheresis                                                                       |
| Laboratory     | Laboratory  tests.                                                                                                                    |
| Final          | Final containers used for Source Plasma, whether integrally attached                                                                  |
| Final          | Final containers and their components shall not interact with                                                                         |
| Source         | Source  Plasma shall not contain a preservative.                                                                                      |
| Source         | Source Plasma intended for manufacturing into injectable products shall                                                               |
| Source         | Source Plasma donated by paid donors determined to be                                                                                 |
| That           | requires two biologics licenses for Source Plasma: Provided, That (1) The results of such tests are maintained                        |
| Research       | undertaken by the Center for Biologics Evaluation and Research , Food and Drug Administration.                                        |
| United States  | the facility is located outside of the continental United States , notification by cable or telegram shall be                         |
| Research       | by the Director, Center for Biologics Evaluation and Research , Food and Drug Administration, of a supplement                         |
| Research       | by the Director, Center for Biologics Evaluation and Research , Food and Drug Administration, based upon his                          |
| Such           | Such evidence may be submitted by either the licensed                                                                                 |
| Color          | Color  coding shall not be used for this purpose.                                                                                     |
| Appropriate    | Appropriate records shall be maintained identifying the units involved,                                                               |
| Albumin        | Albumin  (Human).                                                                                                                     |
| Source         | (b)  Source  material.                                                                                                                |
| Albumin        | The source material of  Albumin (Human) shall be plasma recovered from Whole Blood                                                    |
| Whole          | of Albumin (Human) shall be plasma recovered from Whole Blood prepared as prescribed in &#167;&#167;&#8201;640.1 through 640.5,       |
| Source         | Source material shall not contain an additive unless it                                                                               |
| Bulk           | Bulk concentrate to be held more than 1 week                                                                                          |
| Albumin        | Heating of the final containers of  Albumin (Human) shall begin within 24 hours after completion                                      |
| Heat           | Heat treatment shall be conducted so that the solution                                                                                |
| Albumin        | All final containers of  Albumin (Human) shall be incubated at 20 to 35                                                               |
| Research       | by the Director, Center for Biologics Evaluation and Research , Food and Drug Administration.                                         |
| Sodium         | (d)  Sodium  concentration.                                                                                                           |
| Albumin        | A final container sample of  Albumin (Human) shall remain unchanged, as determined by visual                                          |
| Turbid         | position on the label, &#8220;Do Not Use if Turbid .                                                                                  |
| Source         | (b)  Source  material.                                                                                                                |
| Whole          | Protein Fraction (Human) shall be plasma recovered from Whole Blood prepared as prescribed in &#167;&#167;&#8201;640.1 through 640.5, |
| Source         | Source material shall not contain an additive unless it                                                                               |
| Bulk           | Bulk concentrate to be held more than 1 week                                                                                          |
| Heat           | Heat treatment shall be conducted so that the solution                                                                                |
| Research       | by the Director, Center for Biologics Evaluation and Research , Food and Drug Administration.                                         |
| Sodium         | (d)  Sodium  concentration.                                                                                                           |
| Turbid         | position on the label, &#8220;Do Not Use if Turbid .                                                                                  |
| Source         | (b)  Source  material.                                                                                                                |
| Whole          | Immune Globulin (Human) shall be plasma recovered from Whole Blood prepared as prescribed in &#167;&#167;&#8201;640.1 through 640.5,  |
| Globulin       | Globulin as either a liquid concentrate or a solid                                                                                    |
| Globulin       | Globulin as a solid free from alcohol and containing                                                                                  |
| Research       | by the Director, Center for Biologics Evaluation and Research , Food and Drug Administration.                                         |
| Potency        | Potency .                                                                                                                             |
| Research       | designated by the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, as indicated in                  |
| Research       | designated by the Center for Biologics Evaluation and Research , Food and Drug Administration, as indicated in                        |
| Research       | (a) The Director, Center for Biologics Evaluation and  Research , may issue an exception or alternative to                            |
| Licensed       | Licensed establishments must submit such requests in accordance with                                                                  |
| Medical        | Medical  supervision.                                                                                                                 |


## Date

| Date       | Context                                                                                                        |
|:-----------|:---------------------------------------------------------------------------------------------------------------|
| 2018-09-01 | (1) Plasma shall be obtained by separating plasma from blood collected from blood donors or by plasmapheresis. |


